Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shuman, Glenn & Stecker : Investigates Emergent BioSolutions, Inc.

09/21/2021 | 01:24pm EST

Shuman, Glenn & Stecker announces that it is investigating potential claims against certain officers and directors of Emergent BioSolutions, Inc. (“Emergent” or the “Company”) (NYSE: EBS). Emergent is a biopharmaceutical company that develops vaccines for infectious diseases.

The Firm’s investigation relates to allegations raised in a securities class action lawsuit filed against Emergent and certain of its senior officers in the U.S. District Court for the District of Maryland. The lawsuit alleges that Emergent signed deals with Johnson & Johnson (“J&J”) and AstraZeneca to provide contract development and manufacturing organization services for production of those companies’ COVID-19 vaccine candidates, and also received federal government funds in connection with Operation Warp Speed. The lawsuit further alleges that the defendants repeatedly touted Emergent’s ability and capacity to mass manufacture COVID-19 vaccines at its Baltimore, Maryland manufacturing site but failed to disclose myriad issues which would detrimentally affect its ability to do so. In April 2020, the U.S. Food and Drug Administration conducted an inspection which revealed serious problems, including deficient containment areas, necessary technology and personnel upgrades, and inadequate employee training.

On March 31, 2021, media reports revealed that ingredients for the J&J and AstraZeneca vaccines were “mixed up” at the Baltimore facility, contaminating up to 15 million doses of J&J’s vaccine. It was further revealed that this was not an isolated incident. By December 2020, Emergent was forced to discard millions of AstraZeneca vaccine doses after they were spoiled by bacterial contamination of equipment. In response, the U.S. Government placed J&J in charge of Emergent’s Baltimore facility and prohibited Emergent from producing the AstraZeneca vaccine. In response, shares of Emergent’s stock price fell by over 15% over the next two trading days to close at $78.62 on April 5, 2021. Emergent’s stock has never recovered and currently trades for approximately $55 per share.

If you currently own Emergent common stock and are interested in discussing your rights, or have information relating to this investigation, please contact Kip Shuman toll free at (866) 569-4531 or email Mr. Shuman at kip@shumanlawfirm.com.

Shuman, Glenn & Stecker represents investors throughout the nation, concentrating its practice in stockholder litigation.


© Business Wire 2021
All news about EMERGENT BIOSOLUTIONS INC.
12/02Special Report-U.S. rushed contracts to COVID-19 suppliers with troubled plants
RE
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) added to S&P 600
CI
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) added to S&P 600 Health Care
CI
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) dropped from S&P 400
CI
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) dropped from S&P 400 Health Care
CI
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) dropped from S&P 400 - Biotechnology
CI
11/24Janssen COVID-19 vaccine plant in Baltimore gets Health Canada OK
AQ
11/24Canada clears import of J&J COVID-19 vaccine doses made at Emergent plant
RE
11/23Thinking about buying stock in Aptevo Therapeutics, Navitas Semiconductor, Berkshire Gr..
PR
11/22SiTime to Join S&P MidCap 400, Pushing Emergent BioSolutions to S&P SmallCap 600 From N..
MT
More news
Analyst Recommendations on EMERGENT BIOSOLUTIONS INC.
More recommendations
Financials (USD)
Sales 2021 1 689 M - -
Net income 2021 230 M - -
Net Debt 2021 371 M - -
P/E ratio 2021 9,85x
Yield 2021 -
Capitalization 2 259 M 2 259 M -
EV / Sales 2021 1,56x
EV / Sales 2022 1,39x
Nbr of Employees 2 200
Free-Float 88,6%
Chart EMERGENT BIOSOLUTIONS INC.
Duration : Period :
Emergent BioSolutions Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EMERGENT BIOSOLUTIONS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 41,99 $
Average target price 57,40 $
Spread / Average Target 36,7%
EPS Revisions
Managers and Directors
Robert G. Kramer President, Chief Executive Officer & Director
Richard Scott Lindahl Chief Financial Officer, Treasurer & Executive VP
Fuad El Hibri Executive Chairman
Sharon M. Solomon Chief Information Officer & Senior Vice President
Christopher H. Cabell Head-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
EMERGENT BIOSOLUTIONS INC.-51.31%2 259
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641